Latest & greatest articles for anastrozole

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anastrozole or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anastrozole and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anastrozole

1. Anastrozole

Anastrozole Top results for anastrozole - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search (...) button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for anastrozole The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory

Trip Latest and Greatest2018

2. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 29482983 2018 04 03 1474-5488 19 4 2018 Apr The Lancet. Oncology Lancet Oncol. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. 474-485 S1470-2045(18)30116-5 10.1016/S1470-2045(18)30116-5 Uncertainty (...) exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly compared the three aromatase inhibitors anastrozole, exemestane, and letrozole. We investigated the schedule and type of aromatase inhibitors to be used as adjuvant treatment for hormone receptor-positive early breast cancer. FATA-GIM3 is a multicentre, open-label, randomised, phase 3 trial of six different treatments in postmenopausal women with hormone

EvidenceUpdates2018

3. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. BACKGROUND: Aromatase inhibitors are a standard of care for hormone receptor-positive locally advanced or metastatic breast cancer. We investigated whether the selective oestrogen receptor degrader fulvestrant could improve progression-free survival compared with anastrozole in postmenopausal patients who had not received previous (...) ) to fulvestrant (500 mg intramuscular injection; on days 0, 14, 28, then every 28 days thereafter) or anastrozole (1 mg orally daily) using a computer-generated randomisation scheme. The primary endpoint was progression-free survival, determined by Response Evaluation Criteria in Solid Tumors version 1·1, intervention by surgery or radiotherapy because of disease deterioration, or death from any cause, assessed in the intention-to-treat population. Safety outcomes were assessed in all patients who received

Lancet2016

4. Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study

Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study 26371134 2015 11 07 2016 02 12 2016 12 15 1527-7755 33 32 2015 Nov 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study. 3781-7 (...) 10.1200/JCO.2015.61.5831 To compare overall survival (OS) for fulvestrant 500 mg versus anastrozole as first-line endocrine therapy for advanced breast cancer. The Fulvestrant First-Line Study Comparing Endocrine Treatments (FIRST) was a phase II, randomized, open-label, multicenter trial. Postmenopausal women with estrogen receptor-positive, locally advanced/metastatic breast cancer who had no previous therapy for advanced disease received either fulvestrant 500 mg (days 0, 14, 28, and every 28 days

EvidenceUpdates2015

5. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. BACKGROUND: Aromatase inhibitors effectively prevent breast cancer recurrence and development of new contralateral tumours in postmenopausal women. We assessed the efficacy and safety of the aromatase inhibitor anastrozole for prevention of breast cancer in postmenopausal women who are at high risk of the disease. METHODS: Between Feb 2 (...) , 2003, and Jan 31, 2012, we recruited postmenopausal women aged 40-70 years from 18 countries into an international, double-blind, randomised placebo-controlled trial. To be eligible, women had to be at increased risk of breast cancer (judged on the basis of specific criteria). Eligible women were randomly assigned (1:1) by central computer allocation to receive 1 mg oral anastrozole or matching placebo every day for 5 years. Randomisation was stratified by country and was done with blocks (size six

Lancet2014

6. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. 24333009 2014 03 24 2014 04 09 2016 11 22 1474-547X 383 9922 2014 Mar 22 Lancet (London, England) Lancet Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. 1041-8 10.1016/S0140-6736(13)62292-8 S0140-6736(13)62292-8 Aromatase (...) inhibitors effectively prevent breast cancer recurrence and development of new contralateral tumours in postmenopausal women. We assessed the efficacy and safety of the aromatase inhibitor anastrozole for prevention of breast cancer in postmenopausal women who are at high risk of the disease. Between Feb 2, 2003, and Jan 31, 2012, we recruited postmenopausal women aged 40-70 years from 18 countries into an international, double-blind, randomised placebo-controlled trial. To be eligible, women had

Lancet2014

7. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr 23902874 2013 09 02 2013 11 04 2016 11 25 1474-5488 14 10 2013 Sep The Lancet. Oncology Lancet Oncol. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal (...) months). Additionally, patients had to have adequate organ function and a WHO performance status of 0-2. Participants were randomly assigned (1:1:1) to receive fulvestrant (500 mg intramuscular injection on day 1, followed by 250 mg doses on days 15 and 29, and then every 28 days) plus daily oral anastrozole (1 mg); fulvestrant plus anastrozole-matched placebo; or daily oral exemestane (25 mg). Randomisation was done with computer-generated permuted blocks, and stratification was by centre

EvidenceUpdates2013

8. Everolimus (Afinitor® or Votubia®) in combination with exemestane in postmenopausal women with oestrogen receptor positive, HER2- negative locally advanced or metastatic breast cancer who are refractory to letrozole or anastrozole

Everolimus (Afinitor® or Votubia®) in combination with exemestane in postmenopausal women with oestrogen receptor positive, HER2- negative locally advanced or metastatic breast cancer who are refractory to letrozole or anastrozole Everolimus (Afinitor® or Votubia®) in combination with exemestane in postmenopausal women with oestrogen receptor positive, HER2- negative locally advanced or metastatic breast cancer who are refractory to letrozole or anastrozole Everolimus (Afinitor® or Votubia (...) ®) in combination with exemestane in postmenopausal women with oestrogen receptor positive, HER2- negative locally advanced or metastatic breast cancer who are refractory to letrozole or anastrozole Jeitler K, Semlitsch T, Nachtnebel A, von Minckwitz G Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Jeitler K, Semlitsch T, Nachtnebel A, von Minckwitz G

Health Technology Assessment (HTA) Database.2012

9. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial

Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial 22265697 2012 04 03 2012 06 22 2014 11 20 1474-5488 13 4 2012 Apr The Lancet. Oncology Lancet Oncol. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. 345-52 10.1016/S1470-2045(11)70373-4 Aromatase inhibitors have shown increased efficacy (...) compared with tamoxifen in postmenopausal early breast cancer. We aimed to assess the efficacy and safety of anastrozole versus tamoxifen in premenopausal women receiving goserelin for early breast cancer in the neoadjuvant setting. In this phase 3, randomised, double-blind, parallel-group, multicentre study, we enrolled premenopausal women with oestrogen receptor (ER)-positive, HER2-negative, operable breast cancer with WHO performance status of 2 or lower. Patients were randomly assigned (1:1

EvidenceUpdates2012

10. Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group

Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group 22271481 2012 02 27 2012 06 08 2014 11 20 1527-7755 30 7 2012 Mar 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal (...) patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. 722-8 10.1200/JCO.2011.36.8993 Anastrozole (ANA) alone delivers significant disease-free survival benefits over tamoxifen (TAM) monotherapy in postmenopausal women with early estrogen receptor-positive breast cancer. The ABCSG-8 (Austrian Breast and Colorectal Cancer Study Group 8) study is a large phase III clinical trial addressing the sequence strategy containing ANA in comparison

EvidenceUpdates2012

11. Cost-effectiveness study of clomiphene citrate versus anastrozole for inducing ovulation in infertile adult patients in a public hospital, La Raza in Mexico City

Cost-effectiveness study of clomiphene citrate versus anastrozole for inducing ovulation in infertile adult patients in a public hospital, La Raza in Mexico City Cost-effectiveness study of clomiphene citrate versus anastrozole for inducing ovulation in infertile adult patients in a public hospital, La Raza in Mexico City Cost-effectiveness study of clomiphene citrate versus anastrozole for inducing ovulation in infertile adult patients in a public hospital, La Raza in Mexico City Martinez (...) Nunez JM, Altagracia Martinez M, Rios C, Kravzov Jinich J, Hinojosa Cruz JC, Vital Reyes VS Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to evaluate the cost-effectiveness of clomiphene citrate versus anastrozole

NHS Economic Evaluation Database.2012

12. Economic evaluation of anastrozole versus tamoxifen for early stage breast cancer in Singapore

Economic evaluation of anastrozole versus tamoxifen for early stage breast cancer in Singapore Economic evaluation of anastrozole versus tamoxifen for early stage breast cancer in Singapore Economic evaluation of anastrozole versus tamoxifen for early stage breast cancer in Singapore Shih V, Chan A, Xie F, Ko Y Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. CRD summary The study estimated the cost-effectiveness postmenopausal women with early (...) stage breast cancer. The authors concluded that, although anastrozole had a higher drug acquisition cost, it was cost-effective for treating early stage breast cancer in Singapore based on effectiveness and utility data. The quality of the study methodology was good, with methods and results reported in detail. Given the scope of the study, the authors’ conclusions appear to be appropriate. Type of economic evaluation Cost-effectiveness analysis, cost-utility analysis Study objective The study

NHS Economic Evaluation Database.2012

13. Combination anastrozole and fulvestrant in metastatic breast cancer.

Combination anastrozole and fulvestrant in metastatic breast cancer. 22853014 2012 08 02 2012 08 09 2016 12 15 1533-4406 367 5 2012 Aug 02 The New England journal of medicine N. Engl. J. Med. Combination anastrozole and fulvestrant in metastatic breast cancer. 435-44 10.1056/NEJMoa1201622 The aromatase inhibitor anastrozole inhibits estrogen synthesis. Fulvestrant binds and accelerates degradation of estrogen receptors. We hypothesized that these two agents in combination might be more (...) effective than anastrozole alone in patients with hormone-receptor (HR)-positive metastatic breast cancer. Postmenopausal women with previously untreated metastatic disease were randomly assigned, in a 1:1 ratio, to receive either 1 mg of anastrozole orally every day (group 1), with crossover to fulvestrant alone strongly encouraged if the disease progressed, or anastrozole and fulvestrant in combination (group 2). Patients were stratified according to prior or no prior receipt of adjuvant tamoxifen

NEJM2012 Full Text: Link to full Text with Trip Pro

14. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer 19786670 2009 11 20 2010 01 05 2015 11 19 1527-7755 27 33 2009 Nov 20 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal (...) to anastrozole (1 mg/d orally) with or without trastuzumab (4 mg/kg intravenous infusion on day 1, then 2 mg/kg every week) until progression. The primary end point was progression-free survival (PFS) in the intent-to-treat population. Results Overall, 103 patients received trastuzumab plus anastrozole; 104 received anastrozole alone. Patients in the trastuzumab plus anastrozole arm experienced significant improvements in PFS compared with patients receiving anastrozole alone (hazard ratio = 0.63; 95% CI

EvidenceUpdates2010

15. Comparing the cost of adjuvant anastrozole with the benefits of managing less patients with relapsed breast cancer

Comparing the cost of adjuvant anastrozole with the benefits of managing less patients with relapsed breast cancer Comparing the cost of adjuvant anastrozole with the benefits of managing less patients with relapsed breast cancer Comparing the cost of adjuvant anastrozole with the benefits of managing less patients with relapsed breast cancer Thomas RJ, Williams M, Glen J, Callam M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study estimated the costs of managing patients with relapsed breast cancer and updated a published economic model. The authors concluded that anastrozole was a preferred option compared with tamoxifen. Given the limited reporting, it is not possible to determine whether or not the authors

NHS Economic Evaluation Database.2009

16. Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II)

Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II) 18768369 2008 12 16 2009 01 14 2016 11 22 1474-5488 9 10 2008 Oct The Lancet. Oncology Lancet Oncol. Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). 953-61 10.1016/S1470-2045(08)70207-9 Mild cognitive impairments have been recorded in cross-sectional studies of women with breast (...) cancer receiving endocrine treatment. More comprehensive studies were warranted because aromatase inhibitors are being used increasingly in both chemoprevention and adjuvant settings. We report findings from the cognitive subprotocol of the International Breast Intervention Study (IBIS II), a double-blind placebo-controlled trial of anastrozole in postmenopausal women at high risk of developing breast cancer. We aimed to study and compare the effect of anastrozole versus placebo on memory

EvidenceUpdates2008

17. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective

Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective Karnon J, Delea T (...) in order to select the most cost-effective alternative. Concluding remarks: This study was adequately conducted, and, on the whole, was clearly and transparently reported. The conclusions reached by the authors reflected the scope of their analysis. Funding Funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Bibliographic details Karnon J, Delea T, Barghout V. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive

NHS Economic Evaluation Database.2008

18. Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer

Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer Aydiner A, Tas F CRD summary This review found that anastrozole was more effective than tamoxifen (...) in adjuvant hormonal treatment of early breast cancer in postmenopausal women, and that aromatase inhibitors should be the initial hormone therapy for its treatment. However, the review did not provide direct evidence for any treatment approach, and this, along with review methodological limitations, imply cautious interpretation of the results. Authors' objectives To assess the impact of upfront, switching and sequencing schedules of anastrozole adjuvant treatment in early breast cancer. Searching

DARE.2008

19. Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial

Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial Cost-effectiveness analysis (...) of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial Mansel R, Locker G, Fallowfield L, Benedict A, Jones D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment

NHS Economic Evaluation Database.2007

20. Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole

Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with (...) breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole Skedgel C, Rayson D, Dewar R, Younis T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined three adjuvant hormonal

NHS Economic Evaluation Database.2007